For Healthcare Professionals

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

clipboard-pencil

About the study

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

* Documented diagnosis of AHP, per physician's determination

EXCLUSION CRITERIA

Exclusion Criteria:

* Currently enrolled in a clinical trial for any investigational agent

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-877-ALNYLAMEmail iconEmail Study Center

Study Details


Contition

Acute Hepatic Porphyria

Age

12+

Participants Needed

150

Est. Completion Date

Apr 1, 2027

Treatment Type

OBSERVATIONAL


Sponsor

Alnylam Pharmaceuticals

ClinicalTrials.gov NCT Identifier

NCT04883905

Study Number

ALN-AS1-006

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.